C. L. Corless

1.1k total citations
21 papers, 830 citations indexed

About

C. L. Corless is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology and Hematology. According to data from OpenAlex, C. L. Corless has authored 21 papers receiving a total of 830 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 6 papers in Gastroenterology and 4 papers in Hematology. Recurrent topics in C. L. Corless's work include Gastrointestinal Tumor Research and Treatment (6 papers), Gastric Cancer Management and Outcomes (6 papers) and Sarcoma Diagnosis and Treatment (4 papers). C. L. Corless is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (6 papers), Gastric Cancer Management and Outcomes (6 papers) and Sarcoma Diagnosis and Treatment (4 papers). C. L. Corless collaborates with scholars based in United States, Switzerland and Canada. C. L. Corless's co-authors include Michael C. Heinrich, Torsten O. Nielsen, Margaret von Mehren, Subbaya Subramanian, Andrew Fire, Matt van de Rijn, Weng‐Onn Lui, I Espinosa, Annick D. Van den Abbeele and George D. Demetri and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Oncogene.

In The Last Decade

C. L. Corless

21 papers receiving 787 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. L. Corless United States 10 387 358 213 166 145 21 830
Jiren Yu China 19 311 0.8× 132 0.4× 230 1.1× 285 1.7× 162 1.1× 56 960
Xiangqian Su China 18 594 1.5× 262 0.7× 324 1.5× 380 2.3× 249 1.7× 103 1.3k
Kojiro Eto Japan 17 444 1.1× 129 0.4× 437 2.1× 229 1.4× 174 1.2× 92 1.0k
Eun Sook Nam South Korea 19 130 0.3× 68 0.2× 241 1.1× 208 1.3× 134 0.9× 65 774
Kyung Han Nam South Korea 14 346 0.9× 53 0.1× 137 0.6× 227 1.4× 154 1.1× 46 832
Atsushi Takeno Japan 17 539 1.4× 118 0.3× 471 2.2× 189 1.1× 80 0.6× 137 945
Christine M. Barnett United States 5 521 1.3× 523 1.5× 242 1.1× 73 0.4× 62 0.4× 8 730
Susanne V. Allander Sweden 12 257 0.7× 98 0.3× 93 0.4× 302 1.8× 115 0.8× 18 728
Keishiro Aoyagi Japan 16 470 1.2× 183 0.5× 330 1.5× 209 1.3× 116 0.8× 67 832
Ilana Kepten Israel 7 256 0.7× 252 0.7× 116 0.5× 196 1.2× 48 0.3× 8 578

Countries citing papers authored by C. L. Corless

Since Specialization
Citations

This map shows the geographic impact of C. L. Corless's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. L. Corless with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. L. Corless more than expected).

Fields of papers citing papers by C. L. Corless

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. L. Corless. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. L. Corless. The network helps show where C. L. Corless may publish in the future.

Co-authorship network of co-authors of C. L. Corless

This figure shows the co-authorship network connecting the top 25 collaborators of C. L. Corless. A scholar is included among the top collaborators of C. L. Corless based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. L. Corless. C. L. Corless is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
DeAngelo, Daniel J., Tracy I. George, Cecelia Perkins, et al.. (2017). Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 32(2). 470–478. 93 indexed citations
2.
Ben‐Ami, Eytan, Constance M. Barysauskas, Margaret von Mehren, et al.. (2016). Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Annals of Oncology. 27(9). 1794–1799. 82 indexed citations
3.
4.
O’Rourke, Robert W., Ashley E. White, Antoinette Olivas, et al.. (2011). Hypoxia-induced inflammatory cytokine secretion in human adipose tissue stromovascular cells. Diabetologia. 54(6). 1480–1490. 122 indexed citations
5.
George, Suzanne, Margaret von Mehren, Michael C. Heinrich, et al.. (2011). A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).. Journal of Clinical Oncology. 29(15_suppl). 10007–10007. 22 indexed citations
6.
Beadling, Carol, Michael C. Heinrich, Kathryn G. Schuff, Brian Druker, & C. L. Corless. (2010). Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a personalized cancer medicine registry.. Journal of Clinical Oncology. 28(15_suppl). 10503–10503. 1 indexed citations
7.
Fletcher, J., et al.. (2010). 252 Polyclonal resistance to kinase inhibition in GIST: Mechanisms and therapeutic strategies. European Journal of Cancer Supplements. 8(7). 83–83. 2 indexed citations
8.
9.
Le, D. Elizabeth, Daniel L. Marks, C. L. Corless, et al.. (2007). Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients. Surgical Endoscopy. 21(9). 1593–1599. 19 indexed citations
10.
Subramanian, Subbaya, Weng‐Onn Lui, I Espinosa, et al.. (2007). MicroRNA expression signature of human sarcomas. Oncogene. 27(14). 2015–2026. 185 indexed citations
11.
Gotlib, Jason, Tracy I. George, C. L. Corless, et al.. (2007). The KIT Tyrosine Kinase Inhibitor Midostaurine (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis (ASM): Interim Results of a Phase II Trial.. Blood. 110(11). 3536–3536. 13 indexed citations
12.
Byrd, Daniel M., G. D. Demetri, Heikki Joensuu, et al.. (2007). Evaluation of imatinib mesylate (IM) in patients with large volume gastrointestinal stromal tumors (GISTs). Journal of Clinical Oncology. 25(18_suppl). 10054–10054. 8 indexed citations
13.
Blanke, Charles D., George D. Demetri, Margaret von Mehren, et al.. (2006). Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate. Journal of Clinical Oncology. 24(18_suppl). 9528–9528. 31 indexed citations
14.
O′Brien, Catherine, Mark Garzotto, Celestia S. Higano, et al.. (2005). Predictors of early relapse in high risk prostate cancer patients treated with neoadjuvant mitoxantrone and docetaxel. Journal of Clinical Oncology. 23(16_suppl). 4640–4640. 1 indexed citations
15.
Schneider‐Stock, Regine, Carsten Boltze, Jerzy Lasota, et al.. (2005). Loss of p16 Protein Defines High-Risk Patients with Gastrointestinal Stromal Tumors: A Tissue Microarray Study. Clinical Cancer Research. 11(2). 638–645. 93 indexed citations
16.
McArthur, Grant A., George D. Demetri, Michael C. Heinrich, et al.. (2004). 28 Molecular and clinical analysis of response to imatinib for locally advanced dermatofibrosarcoma protuberans. European Journal of Cancer Supplements. 2(8). 13–13. 5 indexed citations
17.
Demetri, George D., Robert S. Benjamin, Charles D. Blanke, et al.. (2004). NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines.. PubMed. 2 Suppl 1. S–1. 132 indexed citations
18.
Gopal, Deepak V., John M. Rabkin, Brian S. Berk, et al.. (2000). TREATMENT OF PROGRESSIVE HCV RECURRENCE POST LIVER TRANSPLANTATION WITH COMBINATION INTERFERON PLUS RIBAVIRIN.. Transplantation. 69(Supplement). S312–S313. 4 indexed citations
19.
Corless, C. L.. (1996). EVALUATING EARLY-STAGE PROSTATE CANCER. Hematology/Oncology Clinics of North America. 10(3). 565–579. 2 indexed citations
20.
Corless, C. L., et al.. (1983). A class of ompA mutants of Escherichia coliK12 affected in the interaction of OmpA protein and the core region of lipopolysaccharide. Molecular and General Genetics MGG. 189(1). 162–165. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiren Yu Breakdown of academic impact, for papers by Xiangqian Su Breakdown of academic impact, for papers by Kojiro Eto Breakdown of academic impact, for papers by Eun Sook Nam Breakdown of academic impact, for papers by Kyung Han Nam Breakdown of academic impact, for papers by Atsushi Takeno Breakdown of academic impact, for papers by Christine M. Barnett Breakdown of academic impact, for papers by Susanne V. Allander Breakdown of academic impact, for papers by Keishiro Aoyagi Breakdown of academic impact, for papers by Ilana Kepten
Rankless by CCL
2026